Elan shares rise on positive finding on Antegen

Shares in Elan rose over 12% in trading on Nasdaq on Tuesday December 31, as a result of a positive report on Antegen and on news of its realising further cash.

Biogen, Inc. and Elan Corporation, plc have announced that the results of a study published in the New England Journal of Medicine (NEJM) indicate ANTEGREN® (natalizumab) reduced new inflammatory brain lesions and relapses in patients with relapsing forms of multiple sclerosis (MS).